ALLG
AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP

Improving the treatment and the lives of patients with blood cancers through clinical trial research

AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP

Trials Newsletter No 5

November 2014

This newsletter is published approximately every two months and provides update information on the ALLG trial program. Other ALLG activities are covered in the general newsletter published three times a year. To see the latest issue click HERE.

ALLG Trial Centre

Fax (Trial Registration, SAEs): +61(0)3 9429 8277

Note new address: 35 Elizabeth St Richmond, Vic

For more trial information visit the Members area at the ALLG website

Transition of ALLG trials

All trials that have been coordinated by BaCT trials are in the process of transitioning to the ALLG Trial Centre. The focus is to make the move as smooth as possible with minimal disruption to essential processes such as registration, randomisation and SAEs. Less active trials are undergoing review prior to closure by an ALLG CRA. Two trials (CLL5, AMLM12) will remain at BaCT until final analysis; with transfer to then follow.

Already in the ALLG Trial Centre from BaCT	AMLM15, AMLM16, CLL6, NHL16	See below for CRAs
Already in ALLG Trial Centre from the Alfred	AMLM18 Registry	See below for CRA
Trials in transition in November/December	ALL06, BM07, CML6, CML9, HD08, HDNHL4, MDS3, MDS4, MM13, NHL21, NHL24, NHL25	See below for CRAs
Closed trials in transition in November/December	ALL5, ALL7, AMLM13, APML4, CML7, CML8, NHL11, SC03, PT1	For further information contact Janey Stone
Completed trials in transition in November/December	AMLM14, HD4, LY03,NHL13, NHL18, NHL19, NHLLOW4, SC01	Formal closure and archiving arrangements TBA
Still in BaCT	CLL5, AMLM12	Transfer date TBA. No change in contact details.

Milestones

- **NHL15 RECRUITMENT CLOSED TO ACCRUAL 3 October 2014**
- **NHL27 CLOSED TO ACCRUAL October 2014**
- **SC04 CLOSED TO ACCRUAL**

Expressions of Interest

The ALLG Trial Centre is currently calling for Expressions of Interest for trial participation. Please reply to the survey registering your interest before the deadline to be considered.

TRIAL	PI	Contact person	Period for EOI
CML11 PINNACLE Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase CML aiming to maximize CMR and MMR	David Yeung, Tim Hughes, Andrew Grigg	Briony Tupper	places remaining
AMLM20 A programme of development for older patients with AML and high risk MDS	Andrew Wei	TBA	EOI opens December 2014
CLL7 An Australasian, phase II, multicentre, randomised, study investigating efficacy and safety for dose reduced fludarabine, cyclophosphamide and iv obinutuzumab (G-FC3) vs oral chlorambucil and iv obinutuzumab (G-Clb) in previously untreated, comorbid (CIRS score ≥6), elderly (≥65 years old) patients with CLL	Stephen Mulligan, Xavier Badoux, Con Tam	TBA	EOI to open January 2015
AMLM21 A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia	Andrew Wei	TBA	Expected to open to EOI April 2015

New ALLG Trial Centre staff

Amanda Jager CRA

Amanda Jager (CRA) started in the ALLG Trial Centre mid November. She has over five years working is clinical research in the Department of Haematology and Oncology at Queen Elizabeth Hospital in Adelaide, and her ability to learn new roles is shown by her strong record of career progression. We are excited that Amanda will add to our knowledge base in the ALLG Trial Centre by giving us first hand knowledge of site procedures. Amanda is already familiar with some ALLG trials from her site participation.

Trials news

Transfer: These trials are **newly transferred** into the ALLG Trial Centre. Please address all correspondence to the new CRA/sCRA listed.

New!: **New trials** are coming on board all the time! If you see this sign it means the trial has just opened or will open in the near future.

Acute Leukaemia/MDS Disease Group

AML/MDS Disease Group Chair Andrew Wei

AMLM18 Registry
CI: Andrew Wei
CRA: Amanda Jager: ALLG Trial Centre
The AMLM18 Registry has completed transition from the Alfred to the ALLG Trial Centre and is now managed by our new CRA Amanda Jager. A round table at the November Scientific Meeting allowed sites to raise concerns and these will be worked on in a systematic manner over the next few months. Please feel free to direct further queries to Amanda or Megan Sandars

Our new Data Manager Sri Joshi is working on the eCRF which is expected to be available to sites in the first half of next year.

AMLM15
CI: Andrew Wei
CRA: Amanda Jager, ALLG Trial Centre
This trial has now completed transition from BaCt to the ALLG Trial Centre where it is being managed by Amanda Jager. Cohort 5 is currently open to accrual.

AMLM16
CI: Andrew Wei
CRA: Andrew Budniak ALLG Trial Centre
This has trial now completed transition to the ALLG Trial Centre. Andrew Budniak would like to encourage any sites with queries or problems to contact him. He will make it a priority to deal with all outstanding issues.

AMLM17
CI: Andrew Wei
CRA: Bala Ravishankar ALLG Trial Centre
Cohort B of the phase I study, with 50 mg lenalidomide and 12 mg/m^2 romidepsin, is currently open at two sites. As a dose limiting toxicity occurred in the first group of 3 patients, the cohort has expanded to 6 patients. If no further DLT occurs, a higher dose cohort may then be opened at the discretion of the TMC.

Andrew Wei raised a concept for a protocol amendment at the November Scientific Meeting. This will be considered over the coming months.

AMLM20 A programme of development for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome
CI: Andrew Wei
CRA: Amanda Jager ALLG Trial Centre
The ALLG will be participating in the UK Li-1 trial for elderly AML led internationally by Cardiff University. Primarily for patients > 60 years with AML or high risk MDS it features the 'pick a winner' style. An initial assessment of novel treatment options leads to an interim analysis which provides a preliminary outcome. This is followed by expansion into a randomised Phase II evaluation stage. This design enables several agents, which may become available, to be assessed over the life of the program. Consequently, not all randomisation options will be open at all times, and new options will be continued to be offered throughout the lifetime of the trial through protocol amendment.

This type of design is of particular advantage to patients as it allows them access to novel treatments at an early stage of development even if their treating hospital is not attracting other early phase clinical trials in this indication. Moreover, the median age of AML/high risk MDS is now 65 years, and many of these patients are unsuitable for conventional intensive treatment strategies but are largely ineligible for most clinical trials offering novel therapies due to their age.

The ALLG is pleased to acknowledge the funding of LFQ in supporting this trial to enable patients to access these novel treatment options. ***The ALLG is seeking a site that would be willing to act as lead site for this HREC submission. Please contact Megan Sanders if you are interested.***

AMLM21 A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia
CI: Andrew Wei
A number of issues held up activating this trial over the past period, however it is now back on track. The ALLG Trial Centre expects to send out EOIs in Q2 2015

ALL5, ALL7, AMLM13 and AMLM14 have also completed transition to the ALLG Trial Centre. If you have queries in relation to any of these please contact Janey Stone.

Aggressive NHL/HL Disease Group

High grade NHL/HL Disease Group Chair Mark Hertzberg

NHL21
CIs: Mark Hertzberg
CRA: Briony Tupper, ALLG Trial Centre
This study has now completed transition to the ALLG Trial Centre.

HDNHL4
CI: Andrew Wirth
CRA: Bereha Khodr, ALLG Trial Centre
This trial has completed transition from BaCT to the ALLG Trial Centre, where it will be managed by Bereha Khodr. The study accrued 45 patients from 6 sites between 2003 and 2009. Final data queries are just being processed and QA is almost complete. The final analysis will be carried out once these functions are complete.

HD8 RATHL
CI: Judith Trotman
CRA: Briony Tupper, ALLG Trial Centre
This trial has completed transition to the ALLG Trial Centre.

HD4, NHL11, NHL13 and NHL18 have also completed transition to the ALLG Trial Centre. For queries please contact Janey Stone.

Multiple Myeloma Disease Group

Multiple Myeloma Disease Group Chair Peter Mollee

MM14
CIs: Andrew Spencer, Anna Kalf
CRA: Nola Kennedy, Alfred Clinical Research Centre
As of October, 105 patients had been registered in this trial of whom 6 did not start treatment. Of the remaining 99, 34 have been randomized, 31 not yet reached this time point and 34 patients have been withdrawn. Biological endpoints are very important in this trial, so please pay special attention to the samples collection schedule.

MM15
CI: Andrew Spencer
CRA: Nola Kennedy, Alfred Clinical Research Centre
This trial from the European Myeloma Network, which is closed to accrual, accrued 17 patients at four sites in Australia with 1500 accrued internationally. The SDMC approved a protocol amendment in July in which lenalidomide maintenance given to all patients was changed from continuous 28 day cycles to 21 days on and 7 days off. In addition, the amendment allows crossover if neuropathy prevents further Velcade exposure.

MM13
CI: Peter Mollee
CRA: Bereha Khodr
The trial has completed transition to the ALLG Trial Centre. Accrual remains steady but slow, with an interim analysis presented at ASH. All states have at least one site—**PLEASE REFER YOUR PATIENTS**

Supportive Care Disease Group

Supportive Care Disease Group Chair: Con Tam

SC04
CI: Penny Schofield
This trial has closed to accrual and a manuscript is in preparation.

FUTuRE Fertility Study
At the ALLG November Scientific Meeting, Antoinette Anazodo presented the FUTuRE Fertility study, a project to evaluate fertility issues in oncology. Sponsored by the Australasian Oncofertility Consortium, the study is a web-based registry oriented to the AYA population who seek fertility preservation. The study will provide information about a range of fertility related issues in cancer patients.

CML/Myeloproliferative Disease Group



CML/MPN Disease Group Chairs: Con Tam, Tim Hughes

CML11 PINNACLE Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase CML aiming to maximize CMR and MMR .
CIs: David Yeung, Tim Hughes, Andrew Grigg.
CRA: Briony Tupper, ALLG Trial Centre
This will be one of the first trials to transition to eCRFs, which will occur early in 2015. **The ALLG Trial Centre is seeking additional sites to participate in this trial. If your site is interested please contact Briony.**

CML6 and CML9 have completed transition to the ALLG Trial Centre. If you have queries in relation to these please contact Bereha Khodr.

CML7, CML8 and PT1 have completed transition to the ALLG Trial Centre. If you have queries in relation to any of these please contact Janey Stone.

Low grade NHL/CLL Disease Group

NHL/CLL Chairs Stephen Mulligan, Campbell Tiley

CLL6
CIs: David Gottlieb, Con Tam
CRA: Andrew Budniak, ALLG Trial Centre
This study has been successfully transferred over from BaCT to the ALLG Trial Centre. Please note that it is possible to register patients pre commencing FCR and you are encouraged to do so. There is no need to wait until randomisation.

In a recent amendment, haematological recovery is now aimed for 3-5 months as opposed to 2 months as stated in the protocol. The CRF sampling times will be clarified in the next update sent out to all participating sites. The Trial Coordinators' Manual has also been updated with a revised Schedule of Assessments table. Please ensure you follow the new table.

In France 34 sites have now been activated with 5 more sites expected to complete activation by the end of the year. Currently there are 52 patients registered at pre-chemotherapy and two of these have been randomised. **Great work!!! Bereha Khodr is the ALLG Trial Centre CRA responsible for managing the French participation.**

CLL7 An Australasian, phase II, multicentre, randomised, study investigating safety and efficacy for dose reduced fludarabine, cyclophosphamide and i.v. obinutuzumab (G-FC3) vs oral chlorambucil and iv obinutuzumab (G-Clb) in previously untreated, comorbid (CIRS score ≥6), elderly (≥65 years old) patients with chronic lymphocytic leukaemia (CLL)
CIs: Stephen Mulligan, Xavier Badoux, Con Tam
CRA: (TBA), ALLG Trial Centre
This trial is expected to open to expressions of interest in January 2015. With an accrual target of 120 patients, accrual is expected to take 3 years. Treatment is of 24 weeks duration with a minimum follow up of 12 months. For further information contact Megan Sanders.

NHL16 PRIMA
CI: John Seymour
CRA: Bala Ravishankar, ALLG Trial Centre.
This trial has completed transition from BaCT to the ALLG Trial Centre and Bala Ravishankar is now managing all aspects of the study. Please contact him with any queries or issues.

The **amendment** to extend the follow up period to 31 Dec 2016 has been approved at 3 sites and is still under review at the other sites The study has so far shown a significant advantage of rituximab in PFS and this has become standard treatment. However there is still no difference in OS. Further follow-up will allow these issues to be addressed as well as additional data on safety and late toxicity to be collected including second malignancies.

Thank you to Janey Stone and Bereha Khodr who have been managing the ethics submission process, which will now will be Bala's responsibility.

NHL27 RELEVANCE
CI: Pauline Warburton
CRA: Bala Ravishankar, ALLG Trial Centre
International accrual closed in October, with three patients accrued in Australia. Thank you to all who participated, including those who were not able to be activated due to faster than anticipated international accrual.

NHLL0W4 has completed transition to the ALLG Trial Centre. If you have queries in relation to this trial please contact Janey Stone.

BMT Disease Group

BMT DG Chair Ian Lewis

BM06
CI: David Ritchie
CRA: Sarah Dewberry, ALLG Trial Centre
Bone marrow transplant has been used for many years, but up to now there has been no prospective trial to provide an evidence base. The Swedish based ALLG BM06 study will have five sites in Australia/NZ. RMH are open to accrual and Royal Adelaide are also activating soon. Christchurch and Wellington have opened the trial independently but are currently transferring to ALLG sponsorship.

BM07
CI: Andrew Grigg
CRA: Bereha Khodr, ALLG Trial Centre
This trial has completed transition to the ALLG Trial Centre. Andrew plans to commence analysis in 2015.

This newsletter was edited by Janey Stone and approved by Delaine Smith and Megan Sanders.

Questions or comments? E-mail us at info@allg.org.au